Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03937453 · ClinicalTrials.gov registry record
A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus
A clinical trial of Pancreatic Cancer and Pancreatic Neoplasms, sponsored by Nuvance Health.
- Recruiting
- Registry status
- 800
- Enrollment target
- 1
- Study location
NCT03937453 is a study of Pancreatic Cancer and Pancreatic Neoplasms that is actively recruiting participants, run by Nuvance Health. The registered enrollment target is 800 participants, above the 390-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (105% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03937453, a study of Pancreatic Cancer and Pancreatic Neoplasms, is actively recruiting participants, sponsored by Nuvance Health.
- RECRUITING
- Registry status
- 800 participants
- Enrollment target
- 1
- Study location
Study Summary
The main goal of this study is to explore the relationship between new-onset diabetes mellitus/deteriorating diabetes and a subsequent diagnosis of pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early stage pancreatic cancer or precursor lesions. Participants will be asked to donate a blood sample at specific intervals for the creation of a bio-bank necessary for the development of a blood based screening test for pancreatic cancer.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MRI/MRCP
Study Locations (1)
Connecticut
- Nuvance Health - Norwalk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2018-01-19 |
| Est. Completion | 2028-01-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03937453
The ClinicalTrials.gov registry entry for NCT03937453 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 390-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (105% higher). The listed sponsor is Nuvance Health, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRI/MRCP is the first listed.
NCT03937453 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT03937453 about?
NCT03937453 is a clinical study titled "A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus". The main goal of this study is to explore the relationship between new-onset diabetes mellitus/deteriorating diabetes and a subsequent diagnosis of pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early stage pancreatic can...
What is the current status of trial NCT03937453?
This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2018-01-19. Estimated completion is 2028-01-19.
What conditions does trial NCT03937453 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Neoplasms.
What interventions are being tested in trial NCT03937453?
The interventions under investigation include: MRI/MRCP (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03937453?
This trial is sponsored by Nuvance Health, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03937453 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.